Theripion

Theripion is a preclinical-stage biotechnology company founded in 2018 and based in Cambridge, USA, with a stated secondary location in Seattle. The company has developed a proprietary Paraoxonase Fusion Protein Platform to create bifunctional therapeutics aimed at diseases involving oxidative stress, inflammation, and dysfunctional lipid metabolism. With a leadership team possessing decades of combined industry experience, Theripion is seeking partnerships and funding to advance its lead candidates, including TR-43 and Ther4, into clinical trials. The company's core value proposition is rescuing patients from conditions like cardiovascular disease, rheumatoid arthritis, and neurodegenerative disorders.

Paraoxonase Fusion Protein Platform: A first-in-class platform for creating bispecific/bifunctional fusion molecules by combining the antioxidant enzyme paraoxonase 1 (PON1) with other therapeutic protein domains (e.g., Fc, ApoA-I, CTLA4). The platform confers a long half-life to PON1 and aims to treat diseases involving oxidative stress and inflammation. US patent issued in December 2024.

Theripion operates in highly competitive spaces with numerous established and emerging players. Its differentiation lies in its first-in-class PON1 fusion platform, but it will compete against large pharma and biotechs with greater resources and more advanced clinical programs across all its target indications.